Revelation Biosciences Inc REVB.OQ REVB.O is expected to show no change in quarterly revenue when it reports results on November 8 for the period ending December 31 2024
LSEG's mean analyst estimate for Revelation Biosciences Inc is for a loss of $2.29 per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts had fallen by about 36.2% in the last three months.
Wall Street's median 12-month price target for Revelation Biosciences Inc is 14.45, above its last closing price of $0.85.
This summary was machine generated November 8 at 23:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)